Press Releases

 HERTFORDSHIRE, England, PITTSBURGH and BENGALURU, India, Dec. 2, 2019 /PRNewswire/ -- Mylan N.V.  (NASDAQ: MYL) and Bioc

BOSTON, Dec. 2, 2019 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (Nasdaq:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein processing, today announced that it received a letter dated November 27,

CAMBRIDGE, England, Dec. 2, 2019 /PRNewswire/ -- SciBite, the award-winning semantic technology company, recently hosted its annual User Group Meeting at the Wellcome Genome Campus in Cambridge UK, where discussions around ontologies, deep learning and FAIR data dominated the day.

SAN JOSE, Calif., Dec. 2, 2019 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on harnessing the body's immune system in the fight against cance

SAN DIEGO, Dec. 2, 2019 /PRNewswire/ -- Evofem Biosciences, Inc. (NASDAQ: EVFM), a clinical stage biopharmaceutical company, today announced positive top-line results from AMPREVENCE, a Phase 2b clinical trial evaluating the efficacy and safety of its lead product candidate Amphora® for the prevention of urogenital chlamydia and gon

BOSTON, Dec. 2, 2019 /PRNewswire/ -- IFM Therapeutics (IFM), a privately-held biopharmaceutical company focused on developing therapies that modulate novel targets in the innate immune system, today announced the closing of a $55.5 million financing and the launch of its third subsidiary, IFM Quattro, as well as a new incubator, IFM Dis

PALO ALTO, Calif., Dec. 2, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD) today announced that the Company has entered into a funding agreement to sell a capped royalty right on global net sales of KSI-301 to Baker Bros. Advisors for $225 million. KSI-301 is Kodiak's investigational therapy being developed for the treatment of

ST. LOUIS, Dec. 2, 2019 /PRNewswire/ -- Centene Corporation (NYSE: CNC) ("Centene") and CVS Health (NYSE: CVS) announced today that, in connection with the previously announced merger agreement between Centene and WellCare Health Plans, Inc. (NYSE: WCG), Centene has entered into a definitive agreement under which CVS Health will acquire Centene's

HOUSTON, Dec. 2, 2019 /PRNewswire/ -- KBR (NYSE: KBR) announced today that it has been awarded a $216 million task order to provide cybersecurity services for the Defense Health Agency (DHA).

The newly founded relationship will combine the research and development ingenuity of Fapon Biopharma with the state-of-art biologics manufacturing services offered by CMAB CMAB will provide a full range of development and manufacturing services for Fapon Biopharma's biologic drug project The first in class biologic was independently discovered and developed by Fapon Biopharma and shows significant